Revvity has set out a long-range growth strategy built around AI-enabled scientific discovery, recurring software revenue and specialised diagnostics. The plan includes double-digit adjusted EPS growth, margin expansion and about US$5 billion of capital capacity through 2031, but formal 2027 guidance is still pending.
- 6%-8% long-term organic growth target for Life Sciences Solutions
- 10%-12% long-term annualised portfolio value growth target for Signals Software
- Double-digit adjusted EPS growth and 75 basis points of operating margin expansion
- Approximately US$5 billion of capital capacity through 2031
- Headcount reduced by about 16% and global property footprint by about 25% since 2023
Revvity sets out a multi-year growth blueprint
Revvity, Inc. (NYSE:RVTY) is pitching itself as a provider of the infrastructure behind AI-driven scientific discovery, with a long-range plan that targets 3% organic revenue growth above underlying markets, 75 basis points of operating margin expansion and double-digit adjusted EPS growth. Management presented the strategy at its 2026 Investor Day, while stressing that the figures are long-term targets rather than formal 2027 guidance.
Signals Software carries the highest growth ambition
The clearest growth lever is Signals Software, Revvity's scientific software platform. The company is targeting 10%-12% long-term annualised portfolio value growth, compared with 6%-8% organic growth for Life Sciences Solutions, 7%-9% for Immunodiagnostics and 3%-5% for Reproductive Health. Signals generated estimated 2026 revenue of about US$260 million, while annual recurring revenue was presented at more than US$100 million and annualised portfolio value at more than US$275 million.
AI strategy links software to laboratory evidence
Revvity's pitch is not simply that laboratories will buy more software. The company is positioning its reagents and instruments as tools for generating richer biological evidence, with Signals connecting experiments, data, analytics and scientific decisions. Its presentation argued that AI can expand the number of hypotheses researchers explore, but that experimental biology remains necessary to validate those hypotheses. That creates a potential role for Revvity across both the physical laboratory and the digital workflow, although the commercial payoff will depend on customer adoption and execution.
Diagnostics and Life Sciences targets remain differentiated
Diagnostics is expected to deliver 5%-7% long-term organic growth, led by a 7%-9% target for Immunodiagnostics and 3%-5% for Reproductive Health. Life Sciences is targeting 7%-9% organic growth overall, combining 6%-8% from Life Sciences Solutions with the faster Signals business. The 2026 estimates exclude the China immunodiagnostics operation under a definitive divestment agreement, an asset sale that had been outlined in the company's China immunodiagnostics sale coverage earlier this month.
Cost reductions are already part of the investment case
The long-range targets are supported by a substantial operating reset. Revvity said headcount fell by about 16% between 2023 and 2026, while global square footage declined by roughly 25% through site consolidation, logistics changes, insourcing, product re-engineering and vendor consolidation. The company also said more than 90% of coding projects use AI and that AI-enabled software engineering has produced a two-to-three-times productivity increase per developer, according to its presentation.
Capital allocation adds flexibility but raises execution demands
Revvity said it expects about US$5 billion of capital capacity through 2031, while maintaining its dividend, continuing share repurchases and pursuing targeted acquisitions across Life Sciences. The presentation also gave an indicative 2027 framework of roughly 6% organic growth and about 20 basis points of margin expansion, but explicitly said formal 2027 guidance would come with the fourth-quarter earnings release. The key test is whether Signals growth, diagnostics expansion and efficiency gains can arrive together without the AI narrative outrunning the underlying laboratory demand.
Bottom Line?
Revvity has supplied investors with an ambitious long-range framework; the next proof point will be formal 2027 guidance and evidence that Signals growth converts into durable earnings and cash flow.
Questions in the middle?
- Can Signals Software sustain 10%-12% annualised portfolio value growth as it expands beyond its established customer base?
- How much of the planned margin expansion will come from recurring operational improvements rather than further cost reduction?
- Will the China immunodiagnostics divestment and targeted acquisitions change the shape of the long-range portfolio?